Last reviewed · How we verify
pentetic acid calcium
At a glance
| Generic name | pentetic acid calcium |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (PHASE1)
- A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (PHASE1, PHASE2)
- Using Platelet-rich Fibrin in Regenerative Endodontic Treatment in Mature Permanent Teeth (NA)
- Comparative Evaluation of Postoperative Pain and Clinical Success (NA)
- Evaluation of Post-Operative Pain Following the Use of Nano-Calcium Hydroxide (NA)
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (PHASE1, PHASE2)
- Calcium Pyrophosphate Deposition (CPPD) Disease (NA)
- DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentetic acid calcium CI brief — competitive landscape report
- pentetic acid calcium updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI